NewAmsterdam Pharma Company

NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.

A proprietary platform focused on selective cholesterol ester transfer protein (CETP) inhibition, optimized for potency, safety, and once-daily oral dosing to overcome historical limitations of the drug class.

NewAmsterdam competes in the lipid-lowering market against generic statins/ezetimibe, injectable PCSK9 inhibitors, oral bempedoic acid, and inclisiran. Its key differentiators are oral administration combined with best-in-class oral LDL-C reduction efficacy (~45-63%). Success hinges on proving cardiovascular outcomes benefit to surpass moderate-efficacy oral agents and challenge injectables.